Development of a practical, asymmetric synthesis of the hepatitis C virus protease inhibitor MK-5172
Jeffrey Kuethe1, Yong-Li Zhong, Nobuyoshi Yasuda
1Process Chemistry, Merck Research Laboratories, P.O. Box 2000, Rahway, New Jersey 07065-0200, USA. Jeffrey_kuethe@merck.com
Organic Letters
|August 8, 2013
Abstract:
The development of a practical, asymmetric synthesis of the hepatitis C virus (HCV) protease inhibitor MK-5172 (1), an 18-membered macrocycle, is described.

